Gilead Remdesivir Price Triggers Analyst Debate on Recouping Investment

In this article Gilead Sciences Inc.’s move to charge less than expected for its coronavirus-fighting drug drew a debate on Wall Street, as analysts sparred over the company’s ability to recoup its more than $1-billion investment in developing and making the medicine. The drug developer announced that commercial patients would pay roughly $3,120 for a […]